×

Do you want to link to this External Site and leave Amgen.co.kr?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this Amgen Site and leave Amgen.co.kr?

YOU ARE NOW LEAVING AMGEN KOREA'S WEB SITE. Amgen Korea takes takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Blincyto

BLINCYTO® Inj. 35 μg

  • Product Name (Korean) 블린사이토®주 35μg
  • Product Name (Engilsh) BLINCYTO®  Inj. 35μg
  • Active Ingredient (Korean) 블리나투모맙
  • Active Ingredient (English) blinatumomab
  • API content 35μg/1 vial
  • Excipients

    Citric Acid Monohydrate, Lysine Hydrochloride (stabilizer, 25.55 mg), Polysorbate 80, Trehalose Dihydrate (stabilizer, 105.0 mg), Sodium Hydroxide

    [IV Solution Stabilizer] 1 vial (10 mL) containsCitric Acid Monohydrate (52.5 mg), Lysine Hydrochloride (2283.8 mg), Polysorbate 80 (10 mg), Sodium Hydroxide (q.s.), Water For Injection (q.s.)

  • Treatment Anti-malignant tumor agent
  • Indications

    1. MRD-positive B-cell Precursor ALL
    THIS DRUG is indicated for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children.

    2. Relapsed or Refractory B cell Precursor ALL
    THIS DRUG is indicated for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children.

  • BLINCYTO® Medication Guide